ArticleJournal of thoracic disease2017

Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.

Pierpaolo Pastina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.